Report cover image

Middle East Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR/Cas9, ZFN), By Delivery Method (Ex Vivo. In Vivo), By Application, By Mode (Contract, In-house), By End Use, By Country, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Aug 29, 2025
Length 90 Pages
SKU # GV20400083

Description

Middle East Genome Editing Market Trends

The Middle East genome editing market size was estimated at USD 272.8 million in 2024 and is projected to reach USD 668.6 million by 2033, growing at a CAGR of 9.78% from 2025 to 2033. This growth is primarily driven by increasing investments in biotechnology research, rising prevalence of genetic disorders, expanding applications of CRISPR and other gene-editing technologies in agriculture and healthcare, and supportive government initiatives to advance genomic medicine. Moreover, strategic collaborations between regional research institutions and global biotech firms further accelerate regional innovation and market expansion.

Widespread Adoption of CRISPR Technologies

The Middle East is witnessing a rapid uptake of CRISPR-based genome editing technologies, driven by their precision, efficiency, and cost-effectiveness compared to earlier methods such as zinc finger nucleases and TALENs. This surge in adoption is closely tied to the region’s pressing healthcare needs, particularly the high prevalence of monogenic disorders like sickle cell anemia, beta-thalassemia, and certain metabolic syndromes. National genomics initiatives in Saudi Arabia, Qatar, and the UAE generate vast genetic datasets, creating fertile ground for CRISPR-enabled research in functional genomics, target validation, and therapeutic development. Growing investment in local research infrastructure and scientist training also reduces reliance on international expertise, accelerating the translation of genome editing from lab research to clinical applications.

Middle East Genome Editing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East genome editing market report based on technology, delivery method, application, mode, end use, and country:
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • (CRISPR)/Cas9
  • TALENs/MegaTALs
  • ZFN
  • Meganucleases
  • Others
  • Delivery Method Outlook (Revenue, USD Million, 2021 - 2033)
  • Ex vivo
  • In vivo
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic Engineering
  • Cell line engineering
  • Animal genetic engineering
  • Plant genetic engineering
  • Others
  • Clinical Applications
  • Diagnostics Development
  • Therapy Development
  • Mode Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract
  • In-house
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Biotechnology and pharmaceutical companies
  • Academic and government research institutes
  • Contract research organizations
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Oman
  • Rest of Middle East
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

90 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology Segment
1.2.2. Delivery Method Segment
1.2.3. Application Segment
1.2.4. Mode Segment
1.2.5. End Use Segment
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Market Model
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Middle East Genome Editing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Widespread adoption of CRISPR technologies
3.2.1.2. National genome programs boosting regional research
3.2.2. Market restraint analysis
3.2.2.1. Challenges concerning clinical translation
3.2.2.2. Regulatory, scientific, and ethical challenges regarding the use of genetically modified products
3.3. Middle East Genome Editing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Middle East Genome Editing Market: Technology Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East Genome Editing Market Technology Movement Analysis
4.3. Middle East Genome Editing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
4.4. (CRISPR)/Cas9
4.4.1. (CRISPR)/Cas9 market estimates and forecasts 2021 to 2033 (USD Million)
4.5. TALENs/MegaTALs
4.5.1. TALENs/MegaTALs market estimates and forecasts 2021 to 2033 (USD Million)
4.6. ZFN
4.6.1. ZFN market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Meganuclease
4.7.1. Meganuclease market estimates and forecasts 2021 to 2033 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Middle East Genome Editing Market: Delivery Method Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East Genome Editing Market Delivery Method Movement Analysis
5.3. Middle East Genome Editing Market Size & Trend Analysis, by Delivery Method, 2021 to 2033 (USD Million)
5.4. Ex Vivo
5.4.1. Ex vivo market estimates and forecasts 2021 to 2033 (USD Million)
5.5. In Vivo
5.5.1. In vivo market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Middle East Genome Editing Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East Genome Editing Market Application Movement Analysis
6.3. Middle East Genome Editing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Genetic Engineering
6.4.1. Genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
6.4.2. Cell Line Engineering
6.4.2.1. Cell line engineering market estimates and forecasts 2021 to 2033 (USD Million)
6.4.3. Animal Genetic Engineering
6.4.3.1. Animal genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
6.4.4. Plant Genetic Engineering
6.4.4.1. Plant genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
6.4.5. Others
6.4.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Clinical Applications
6.5.1. Clinical applications market estimates and forecasts 2021 to 2033 (USD Million)
6.5.2. Diagnostics Development
6.5.2.1. Diagnostics development market estimates and forecasts 2021 to 2033 (USD Million)
6.5.3. Therapy Development
6.5.3.1. Therapy development market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Middle East Genome Editing Market: Mode Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Middle East Genome Editing Market Mode Movement Analysis
7.3. Middle East Genome Editing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
7.4. Contract
7.4.1. Contract market estimates and forecasts 2021 to 2033 (USD Million)
7.5. In-house
7.5.1. In-house market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Middle East Genome Editing Market: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Middle East Genome Editing Market End Use Movement Analysis
8.3. Middle East Genome Editing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.4. Biotechnology and Pharmaceutical Companies
8.4.1. Biotechnology and pharmaceutical companies market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Academic and Government Research Institutes
8.5.1. Academic and government research institutes market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Contract Research Organizations
8.6.1. Contract research organizations market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Middle East Genome Editing Market: Country Estimates & Trend Analysis
9.1. Country Market Share Analysis, 2024 & 2033
9.2. Country Market Dashboard
9.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
9.4. Middle East
9.4.1. Saudi Arabia
9.4.1.1. Key country dynamics
9.4.1.2. Competitive scenario
9.4.1.3. Regulatory landscape
9.4.1.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
9.4.2. UAE
9.4.2.1. Key country dynamics
9.4.2.2. Competitive scenario
9.4.2.3. Regulatory landscape
9.4.2.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
9.4.3. Kuwait
9.4.3.1. Key country dynamics
9.4.3.2. Competitive scenario
9.4.3.3. Regulatory landscape
9.4.3.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
9.4.4. Qatar
9.4.4.1. Key country dynamics
9.4.4.2. Competitive scenario
9.4.4.3. Regulatory landscape
9.4.4.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)
9.4.5. Oman
9.4.5.1. Key country dynamics
9.4.5.2. Competitive scenario
9.4.5.3. Regulatory landscape
9.4.5.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
9.4.6. Rest of Middle East
9.4.6.1. Key country dynamics
9.4.6.2. Competitive scenario
9.4.6.3. Regulatory landscape
9.4.6.4. Rest of Middle East market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company/Competition Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2024
10.4. Company Profiles/Listing
10.4.1. Merck KGaA
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Takara Bio Inc.
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. Revvity, Inc.
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Danaher Corporation
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. GenScript
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. New England Biolabs
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Charles River Laboratories
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Eurofins Scientific
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. Lonza
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Thermo Fisher Scientific, Inc.
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us